Do we need strategies to manage low-density lipoprotein-cholesterol (LDL-C)?

Peter J. Lansberg, Groningen, discusses if the practising clinicians need strategies to manage low-density lipoprotein-cholesterol (LDL-C) in this pre-recorded webinar, which has been hosted and developed by Viatris.

SPEAKER DETAILS

Peter J. Lansberg
MD PhD

Lansberg is a lipidologist and senior staff member at the Department of Pediatrics, Section Molecular Genetics University Medical Centre Groningen, the Netherlands. Lansberg obtained his Bachelor, Master and Doctor of Medicine degrees from the University of Amsterdam (UvA).

He returned to the Academic Medical Center (AMC) where he worked on his doctoral thesis 'The Molecular Basis and Treatment of Familial Hypercholesterolemia (FH)' at the department of vascular Medicine under the supervision of Prof. John Kastelein and Prof. Jan Wouter ten Cate.

 

 

EDUCATIONAL OBJECTIVES

Speaker: Peter J. Lansberg MD PhD
Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

Title of the session: Do we need strategies to manage low-density lipoprotein-cholesterol (LDL-C)? An update for practising clinicians

Objectives:

  1. Highlight the importance of primary and secondary cardiovascular events prevention with a case presentation
  2. Understanding cholesterol levels and their role in atherosclerosis
  3. Importance of early cholesterol management in the prevention
  4. Strategies to lower cholesterol levels and the concept of ‘cholesterol burden’
  5. Emphasis on the role of long-term statin therapy in LDL-C management
  6. Exploring the safety of statins in comparison with other treatment options
  7. Discuss costs of cholesterol-lowering drugs, and the need for new treatment modalities
  8. Understanding the concept of ‘HELP’, the role of early treatment initiation, and guideline recommendations

Conclusion:

  • Improving CVD risk reduction remains a priority in health care
  • Normal cholesterol = <70 mg/dL
  • Preventive strategies should start early in life/disease1
  • Single pill combination (atorvastatin/ezetimibe) ensures a fast, safe and cost-effective LDL-C reduction1
  • Current ESC guidelines advocate a step wise approach for LDL-C (and blood pressure control)1
  • Initiate personalized medicine strategies with new/upcoming drugs for those patients with 'special needs'

CVD, Cardiovascular Disease; LDL, Low-density lipoprotein

References

  1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188.

NON-2023-5877

RELATED CONTENT